HLA-DQA1
HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.
Overview
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Pleural Mesothelioma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.
- 1 · What it is
HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.
- 2 · What goes wrong in cancer
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
- 3 · How drugs use it
No product in this corpus aims at HLA-DQA1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:4942 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01909 (protein name, function text, keywords and locations (REST API)); IntOGen HLA-DQA1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. Location: Cell membrane; Endoplasmic reticulum membrane; Golgi apparatus, trans-Golgi network membrane; Endosome membrane (UniProt). Locus 6p21.32 (HGNC).
- Mesothelioma: IntOGen driver in 1 cohort (PLMESO)
- Pleural mesothelioma: IntOGen driver in 1 cohort (PLMESO)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HLA-DQA1" OR ABSTRACT:"HLA-DQA1" OR TITLE:"major histocompatibility complex, class II, DQ alpha 1" OR ABSTRACT:"major histocompatibility complex, class II, DQ alpha 1" OR TITLE:"HLA class II histocompatibility antigen, DQ alpha 1 chain" OR ABSTRACT:"HLA class II histocompatibility antigen, DQ alpha 1 chain" OR TITLE:"CELIAC1" OR ABSTRACT:"CELIAC1" OR TITLE:"HLA-DQA" OR ABSTRACT:"HLA-DQA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-DQA1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPDZD2
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetPI4KA
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetSHTN1
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetSRGAP3
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetCYP2C8
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetTAF15
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetNIN
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetTRAF7
Shares Pleural mesothelioma, Mesothelioma, IntOGen.